Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700332 · ClinicalTrials.gov registry record · Phase 2
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Hoag Memorial Hospital Presbyterian.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 1
- Study location
NCT04700332: Recruiting Phase 2 study of Prostate Cancer, sponsored by Hoag Memorial Hospital Presbyterian.
NCT04700332 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Hoag Memorial Hospital Presbyterian. The registered enrollment target is 184 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04700332, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Hoag Memorial Hospital Presbyterian.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 1
- Study location
Study Summary
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.
Primary Outcome
Determine the rate of detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or radiation therapy.
Conditions Studied
Interventions
- DRUG DCFPyL PET/CT
Study Locations (1)
California
- Hoag Memorial Hospital Presbyterian - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 2 |
What NCT04700332 shows while recruiting
NCT04700332 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which DCFPyL PET/CT is the first listed.
NCT04700332 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04700332 about?
NCT04700332 is a clinical study titled "PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer". The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate ca...
What is the current status of trial NCT04700332?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2021-02-01. Estimated completion is 2022-12-15.
What conditions does trial NCT04700332 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04700332?
The interventions under investigation include: DCFPyL PET/CT (DRUG).
Who is sponsoring clinical trial NCT04700332?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04700332 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04700332's enrollment target sits among peer trials
184 239th of 735 higher than 497 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI